“They denied human-to-human transmission until late January. Taiwan had evidence of human-to-human transmission in December and alerted the Chinese health authority. What happened then?“
Not true. It was the WHO that waffled about and took their time confirming human to human transmission. China told the WHO on 7 January when the virus was isolated and sequenced. Subsequent reports from other countries and contact tracing showed it was human to human. However, the WHO took until 23 January to assess the evidence and finally confirm human to human transmission.
5 Jan China report
“Based on the preliminary information from the Chinese investigation team, no evidence of significant human-to-human transmission and no health care worker infections have been reported.”
“WHO does not recommend any specific measures for travellers. In case of symptoms suggestive of respiratory illness either during or after travel, travellers are encouraged to seek medical attention and share travel history with their healthcare provider.
WHO advises against the application of any travel or trade restrictions on China based on the current information available on this event.”
Even on 14 Jan after the Thailand case, the WHO risk assessment stated
“Additional investigation is needed to ascertain the presence of human-to-human transmission, modes of transmission, common source of exposure and the presence of asymptomatic or mildly symptomatic cases that are undetected. It is critical to review all available information to fully understand the potential transmissibility among humans.”
16 Jan when first case reaches Japan, the WHO is still saying
“Much remains to be understood about the new coronavirus, which was first identified in China earlier this month. Not enough is known about 2019-nCoV to draw definitive conclusions about how it is transmitted, clinical features of disease, or the extent to which it has spread. The source also remains unknown.
WHO encourages all countries to continue preparedness activities. On 10 January, WHO published information on how to monitor for cases, treat patients, prevent onward transmission in health care facilities, maintain necessary supplies, and communicate with the public about 2019-nCoV. The information includes advice on how to maintain hand and respiratory hygiene, and safe food and market practices. WHO is developing and updating this information in consultation with networks of experts across the globe.
WHO’s interim guidance and other information on coronaviruses can be found here
WHO advises against the application of any travel or trade restrictions based on the information available. If travellers develop respiratory illness before, during or after travel, they should seek medical attention and share travel history with their health care provider.”
21 Jan and the WHO is sort of admits human to human transmission
“WHO risk assessment
This is the fourth internationally exported case of 2019-nCoV from Wuhan City, China by travelers. Since the initial report of cases on 31 December 2019, and as of 20 January 2020, 278 laboratory-confirmed cases of 2019-nCoV infection including six deaths were reported to WHO globally from China, two cases from Thailand, one case from Japan, and one case from the Republic of Korea. In China, 51 are severe cases, and 12 cases are critically ill. They are all under isolation treatment at designated medical institutions in Wuhan. Among the cases reported in China, 14 cases have been reported from Guangdong province, five from Beijing municipality and one from Shanghai municipality.
The source of the outbreak is still under investigation in Wuhan City. Preliminary investigations have identified environmental samples positive for nCoV in Huanan Seafood Wholesale Market in Wuhan City, however some laboratory-confirmed patients did not report visiting this market. Cases continue to be reported from Wuhan City, and from other provinces in China. Additional investigations are needed to determine how the patients were infected, the extent of human-to-human transmission, the clinical spectrum of disease, and the geographic range of infection”